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1 MUs/microglia per case, using terminal continuation RNA amplification and a custom-designed array platform. Results: Several classes of microglial transcripts in HIVE and HIV/noE were altered, relative to HIV 2 subjects, including factors related to cell stress, immune activation, and apoptosis. Additionally, several neurotrophic factors were reduced in HIV infection, suggesting an additional mechanism of neuropathogenesis. The majority of transcripts altered in HIVE displayed intermediate changes in HIV/noE. Interpretation: Our results support the notion that microglia contribute to the maintenance of brain homeostasis and their potential loss of function in the context of chronic inflammation contributes to neuropathogenesis. Furthermore, they indicate the utility of profiling MUs/microglia to increase our understanding of microglia function, as well as to ascertain alterations in specific pathways, genes, and potentially, encoded proteins that may be amenable to targeted treatment modalities in diseases affecting the brain. ANN NEUROL 2018; 83:406-417 V arying degrees of neurocognitive dysfunction remain a common complication of human immunodeficiency virus (HIV) infection, even in the context of successful pharmacological intervention. Collectively referred to as HIV-associated neurocognitive disorders (HAND), impairment ranges from mild to severe, and significantly impacts the quality of life of those living with HIV. Combination antiretroviral therapy (cART) has decreased the incidence of the most severe form of neurocognitive impairment, HIV-associated dementia (HIV-D), which has as one of its substrates perivascular cuffs and nodular lesions of microglia and macrophages (MUs). These sites serve as the major reservoir of productive virus in the neuropathological HIV-D correlate, HIV encephalitis (HIVE) . 1 Yet, even in the absence of productive virus with HIV infection, irrespective of pharmacological intervention. 2 This is evidenced not only by expression of markers that suggest inflammatory responses by astrocytes and microglia, but also by prominent morphological changes of the 2 cell types indicative of an activated state. 2 This expands on earlier histopathological studies performed before and after the introduction of highly active antiretroviral therapy that demonstrate widespread microglial activation in HIV infection, even in the absence of viral products. [3] [4] [5] Together, these findings provide critical insights into the mechanisms of the less severe form of HAND, minor neurocognitive disorder (MND), which is observed frequently in the cART era, and support the contention that chronic inflammation of the brain plays a key role in the pathogenesis of all forms of HAND. Persistent central nervous system (CNS) inflammation is associated with, and may even predispose individuals to, many neurodegenerative diseases. [6] [7] [8] Moreover,
neuroinflammation is recognized as a major component of several neurocognitive and psychological disorders, including Alzheimer disease, major depressive disorder, and schizophrenia. 9, 10 How inflammation contributes to neurocognitive impairment is not completely clear; however, several inflammation-associated factors, including cytokines, chemokines, and reactive oxygen and nitrogen species from activated microglia can directly and/or indirectly promote neuronal injury or death. Additionally, continuing advances in our understanding of the role of microglia in neuronal function and maintaining CNS homeostasis suggest that microglia may also contribute to neuropathogenesis through mechanisms other than those associated with immunological processes. As such, the varying degrees of neurocognitive dysfunction observed in the context of HIV infection may also be a consequence of chronic neuroinflammation that impairs microglial function.
To further understand microglial function in the context of chronic inflammation, we investigated expression of specific classes of transcripts and individual genes by parenchymal MUs/microglia isolated from brain of patients with HIVE, HIV infection without encephalitis (HIV/noE), and seronegative (HIV 2 ) controls. Customdesigned microarray analyses on laser capture microdissected CD163 1 , CD16 
Materials and Methods
Human Subjects and Tissue Acquisition
Formalin-fixed paraffin-embedded frontal white matter (FWM) from patients with HIVE, patients with HIV/noE, and HIV 2 patients without CNS disease were provided by the Manhattan HIV Brain Bank (MHBB), a member of the National Neuro-AIDS Tissue Consortium (NNTC; U24 MH100931). All tissues were acquired under the Mount Sinai Institutional Review Board approved protocol 98-477(0003) and institutional policy for protection of human subjects Federalwide Assurance number 00005656. Written, informed consent was obtained from all subjects at the time of enrollment into the MHBB of NNTC. Both HIV groupings included patients on and off cART at the time of death (Table) . HIV-D, minor cognitive motor disorder, and normal cognition designations were determined by a licensed MHBB neuropsychologist in accordance with the Dana modification of the American Academy of Neurology criteria 11,12 as described. 2 All HIV/noE subjects in our study demonstrated some degree of neurocognitive impairment. Cognitive status was available for 7 of the 9 HIVE subjects in our study. The retrospective ascertainment of encephalopathy at the time of autopsy for the 2 HIVE subjects who had not undergone neuropsychological testing suggests that these individuals similarly had impaired cognition in life. n/a n/a 567 HIV
Immunohistochemistry
Autopsy FWM samples from of 9 HIVE, 10 HIV
1
/no E, and 5 seronegative (HIV 2 ) individuals without CNS disease were investigated. a NI is an assigned value (01 to 41) based on the overall severity of neuroinflammation, as determined by our previous histopathological evaluation that investigated specific macrophage/microglial (CD16, CD163, and HLA-DR) and astrocytic (GFAP and vimentin) markers of inflammation. 2 The majority of seronegative individuals had very mild indications of neuroinflammation. Morphological alterations suggestive of inflammation/activation of microglia and astrocytes, such as thickened/retracted cell processes and loss of individual cellular domains, were also used to assign the NI value for each case. b Individuals were assigned a degree of positivity (1) or listed as negative (neg) for evidence of productive HIV infection in FWM. These values were derived from our previous immunohistochemical studies investigating HIVp24 protein expression, as well as in situ hybridization. /no E 5 HIV without encephalitis; HIV-D 5 HIV-associated dementia; HIVE 5 HIV encephalitis; M 5 male; MCMD 5 minor cognitive motor disorder; ms change 5 mental status change (patient has altered cognitive capacity; however, the individual observing this is unsure if this constitutes dementia or a transient abnormality); n/a 5 not applicable; n/d 5 not done; NI 5 neuroinflammation index; npi-o 5 neuropsychological impairment-other (patient is cognitively impaired and the observer believes there are enough ancillary factors/comorbid processes to account for the dementia); PID 5 patient identifier; po 5 possible (confounds exist, but observer believes cognitive impairment is most likely HIV-associated); pr 5 probable (no confounds); VL 5 viral load; W 5 white.
fluorescence. Following dehydration, tissues were allowed to air dry in a dark, protected area at least 3 days prior to laser capture microdissection (LCM). Tissue sections on Plus slides (Thermo Fisher Scientific) were immunostained in tandem with tissues on PEN membrane slides, coverslipped with Permount (Thermo Fisher Scientific), and viewed by light microscopy to verify specificity of staining.
LCM and RNA extraction
LCM and terminal continuation (TC) RNA amplification procedures have been described in detail previously by our group. [14] [15] [16] [17] Approximately 2,500 microglia from FWM of each study subject were microaspirated via LCM (Arcturus PixCell IIe; Thermo Fisher Scientific, South San Francisco, CA). A rhodamine filter cube was used to identify Vector Red-positive CD163 were reverse transcribed, and single-stranded cDNAs were then subjected to RNase H digestion and reannealing of the primers to generate cDNAs with double-stranded regions at the primer interfaces. Single stranded cDNAs were digested, and samples were purified by Vivaspin 500 columns (Sartorius Stedim Biotech, Goettingen, Germany). Hybridization probes were synthesized by in vitro transcription using 33 P, and radiolabeled TC RNA probes were hybridized to custom-designed cDNA arrays without further purification.
Custom-Designed Microarray Platforms and Hybridization
Array platforms consist of 1lg of linearized cDNA purified from plasmid preparations adhered to high-density nitrocellulose (Hybond XL; GE Healthcare, Piscataway, NJ) using an arrayer robot (VersArray; Bio-Rad, Hercules, CA 
Statistical Analyses
Statistical procedures for custom-designed microarray analysis using postmortem human brain tissues have been described in detail previously. 17, 23 HIVE, HIV/noE, and HIV 2 subjects were compared with respect to the hybridization signal intensity ratio of 576 genes. For each gene, the signal intensity ratio was modeled using mixed effects models with random effect to account for the correlation between repeated assays in the same subject. 24 Significance was judged at the a 5 0.01 level (2-sided); false discovery rate based on an empirical null distribution due to strong correlation between genes 25, 26 was controlled at the a 5 0.1 level. Expression levels were graphed using a bioinformatics software package (GeneLinker Gold, Predictive Patterns, Kingston, ON, Canada).
Results
Significant Overall Expression Level Changes in HIVE and HIV/noE Relative to HIV 2 Microglia Results indicated significant (p < 0.02) downregulation of the majority of transcripts evaluated on the customdesigned array for HIVE (63.7%; a total of 367/576 genes significantly downregulated) and HIV/noE (22.9%; a total of 132/576 genes significantly downregulated) relative to HIV 2 , indicating a massive effect of HIV infection and chronic inflammation on the genetic fingerprint of microglia. In contrast, statistically significant upregulation was observed in a relatively small subset of genes in HIVE (10.4%; a total of 60/576 genes) and HIV/noE (5.2%; a total of 30/576 genes) compared to HIV 2 .
Alterations in Stress-Related and Immunological Transcripts in HIV Infection
Several stress-associated factors are significantly reduced in HIVE, relative to seronegative subjects, with intermediate expression seen in HIV/noE subjects (Fig 1) . Specifically, downregulation of heat shock proteins Dnaja1, Hspd1, Hspa1a, and Hsp90aa1, as well as both the constitutive and inducible forms of nitric oxide synthase Nos1 and Nos2a, and superoxide dismutase (SOD) Sod1 and Sod2 was found. In addition, factors associated with ameliorating or suppressing inflammation are decreased in HIV/noE and HIVE, including apolipoprotein E (Apoe) and colony stimulating factor 1 (Csf1), whereas key proinflammatory interleukins IL-1b and IL-6 were significantly upregulated. Upregulation of the serpin peptidase inhibitor Serpina3 and a primary tumor necrosis factor alpha (TNFa) receptor, Tnfrsf1a, further supports chronic proinflammatory stimulation and signaling in HIV infection.
Dysregulation of Microglia-Derived Neurotrophic Factors
Relative to seronegative controls, several microgliaderived neurotrophic factor transcripts are downregulated in HIV infection, with and without encephalitis (Fig 2) , including brain-derived neurotrophic factor (Bdnf ), glial cell-derived neurotrophic factor (Gdnf ), and ciliary neurotrophic factor (Cntf ). Upregulation of neurotrophic factors is rarely observed, with statistical significance reached primarily in those with encephalitis (see Fig 2B) . 
Dysregulation of Select Caspase mRNAs
We observed downregulation of several caspases that induce pyroptotic cell death, including caspase Casp1, Casp4, and Casp5, despite overwhelming evidence of sustained neuroinflammation (Fig 3) . Executioners of cell death Casp3 and Casp6 are also downregulated in HIV/noE and HIVE, whereas Casp7 is significantly increased in both HIVE and HIV/noE relative to HIV 2 subjects. Initiators of cell death in extrinsic (Casp8) and intrinsic (Casp9) apoptotic pathways, respectively, are upregulated in HIVE and HIV/noE relative to HIV 2 subjects. Proapoptotic factors, bcl2-antagonist of cell death (Bad), and bcl2-associated x protein (Bax), as well as related mediators of apoptotic pathways including fas-associated via death domain (Fadd), fas ligand receptor (Faslr), and TNFRSF1A-associated via death domain (Tradd) are significantly downregulated in HIVE (see Fig 3A) . Interestingly, B-cell lymphoma 2 (Bcl2), which can inhibit or induce cell death, did not differ significantly among the 3 groups investigated.
Microglial Production of Ubiquitously Expressed Transcription Factors Is Decreased in HIVE and
HIV/noE Downregulation of key transcription factors nuclear factor kappa B (Nfkb), specific protein 1 (Sp1), and cAMP responsive element-binding protein (Creb) is observed in HIVE and HIV/noE microglia (Fig 4) . The ubiquitously expressed transcriptional coactivator CREB-binding protein (Crebbp) is also significantly decreased in both HIV groups.
Select Protein Kinase and Phosphatase Transcripts Are Dysregulated in HIVE and HIV/ noE
The majority of significantly altered protein kinase and phosphatase transcripts on the custom-designed array are downregulated in HIVE and HIV/noE (Fig 5) . Downregulated kinases include protein kinase B (Akt), glycogen synthase kinase-3b (Gsk3b), protein tyrosine kinase 2b (focal adhesion kinase; Ptk2b), and mitogen-activated protein kinase 3 (Mapk3) among several others. Downregulated protein phosphatase subunits include protein phosphatase 1, catalytic subunit, a isoform (Ppp1ca), protein phosphatase 1, catalytic subunit, b isoform (Ppp1cb) protein phosphatase 2, catalytic subunit, a isoform (Ppp2ca), protein phosphatase 2, catalytic subunit, c isoform (Ppp2cg), and protein phosphatase 3, catalytic . Notably, the initiators of cell death, Casp8 (A) and Casp9 (B), are increased in HIV, as compared to noninfected persons, with an even greater increase seen in HIVE. (B) Executioner Casp7 is elevated in HIV infection with and without encephalitis, whereas Casp6 is increased in HIV 1 but decreased in HIVE. Interestingly, Casp3, which cleaves and activates Casp6 and Casp7, is decreased in both HIV groups. *p < 0.02, **p < 0.001, ***p < 0.0001. BAD 5 bcl2-antagonist of cell death; BAX 5 bcl2-associated x protein; BCL2 5 b-cell lymphoma 2; CASP 5 caspase; FADD 5 fas-associated death domain; FASLR 5 fas ligand receptor; GADD45 5 growth arrest and DNA-damageinducible protein; TRADD 5 TNFRSF1A-associated via death domain. [Color figure can be viewed at www.annalsofneurology.org] subunit, a isoform (Ppp3ca) among several others. These coordinated expression level changes in protein phosphatases and kinases may indicate microglial senescence, which has been demonstrated in the context of long-term inflammation in the brain. In contrast, only the mitochondrial kinase anchoring protein A-kinase anchor protein 1 (Akap1) and mitogen-activated protein kinase 1 (Mapk1) are significantly increased in HIV infection (see Fig 5B) .
Discussion
Microglia have been implicated as key players in promoting and advancing neurodegenerative disease, largely through immune activation and associated soluble factors that are directly or indirectly neurotoxic. Proinflammatory cytokines TNFa, IL-1b, and IL-6, as well as increased reactive oxygen species (ROS) and reactive nitrogen species, can be injurious to healthy cells and are commonly seen in brain or cerebrospinal fluid of individuals suffering CNS disease, including HIVE. [27] [28] [29] In our study, both HIV groups demonstrated altered transcripts related to immune activation including the proinflammatory cytokines IL-1b and IL-6, and the major TNFa receptor Tnfrsf1a.
Increased transcription of IL-6 and Tnfrsf1a supports our earlier immunohistochemical findings within the same subjects that show substantial widespread microglial activation in HIV, including individuals on cART prior to death and without detectable virus in brain. 2 We suggested that neuroinflammation is a common complication of HIV infection that may impact the severity of HAND; however, cART was not effective in the majority of patients studied, as evidenced by high plasma viral loads and low CD4 1 T-cell counts. Thus, our study may not be relevant in determining whether neuroinflammation is present in aviremic patients with immunologic reconstitution. Recent positron emission tomography neuroimaging revealed microglial activation in living HIV 1 subjects under successful pharmacological intervention with restored CD4 1 T cells and without cognitive impairment. 30, 31 These findings support the notion that neuroinflammation is common to HIV infection and continues under effective cART. In contrast to IL-6 and Tnfrsf1a, transcription of IL-1b was only upregulated in HIVE. Interestingly, Casp1, which cleaves IL-1b into its active form, 32 was modestly downregulated in both HIV groups. As such, it is unclear if increased transcription of IL-1b in HIVE is associated with increased activity of this important pyrogen. Downregulation of genes was far more common than upregulation in both HIV groups, as compared to seronegative donors. An unprecedented number of genes were impacted in HIVE patients, with downregulation of 63.7% of genes interrogated. By contrast, 22.9% of genes were downregulated in HIV/noE. Overall, this indicates a substantial influence of HIV infection and chronic inflammation on the genetic fingerprint of vulnerable microglia.
Decreased levels of factors associated with resolving immune responses may also perpetuate neuroinflammation. Tissue MUs, including microglia, participate in all aspects of immunity, including promoting and resolving inflammation. To perform these diverse functions, monocyte/MU activation is considerably plastic and heterogeneous, broadly classified into classically activated "proinflammatory" (M1) and alternatively activated "anti-inflammatory" (M2) MUs. M1-associated stimuli IL-6 and IL-1b are increased in HIV, whereas a number of transcripts associated with M2 activation are decreased, including Csf1, Sod1, and Sod2.
A key MU hematopoietic factor, CSF1 (macrophage colony-stimulating factor [M-CSF]), promotes M2-like activation of MUs. In brain of simian immunodeficiency virus-infected rhesus macaques, increased M-CSF expression by MUs that accumulate perivascularly and within nodular lesions corresponds with the principal reservoir of productive virus 33 ; however, parenchymal microglia had less detectable M-CSF, as compared to noninfected animals. 34 Here, we show Csf1 transcription by parenchymal microglia is not significantly changed in HIV/noE or HIVE, as compared to seronegative controls, although a trend toward downregulation is seen in HIVE. How reduced CSF1 transcription impacts HIV neuropathogenesis remains unknown, but it may impair microglial survival. Ligation of the translated product to its cognate receptor, Cfms, activates several signaling cascades that mediate MU survival through suppression of the "initiator caspase," Casp9, and/or activation of Erk. Our studies show a significant increase in Casp9 transcription in both HIV groupings that is greatest in HIVE. Similarly, the "executioner caspase," Casp7, is significantly increased in HIVE, with intermediate is also reduced at the transcription level in HIVE. Activated MUs/microglia produce high levels of ROS, which are needed to perform a variety of functions, such as phagocytosis. Disproportionate levels of ROS, however, can promote cellular oxidative stress, and accumulation of ROS is often seen in the context of neuroinflammation. SODs assist in reducing ROS through enzymatic dismutation of superoxides to hydrogen peroxide. They may also help in resolving inflammation, as SOD1 has been demonstrated to directly mediate M2 polarization. 36 Here, we found microglia-associated Sod1
and Sod2 are downregulated in HIV, which could profoundly impact microglial health and function, as lost or reduced SODs would, presumably, impair the ability of microglia to kill and/or degrade ingested particles. The consequence of reduced microglial Apoe is unclear but may also contribute to chronic neuroinflammation. APOE exists in 3 isoforms, APOE2-4. The E4 variant is associated with increased CNS inflammation and oxidative stress and is a genetic risk factor for several CNS pathologies. [37] [38] [39] Interestingly, proinflammatory cytokines in APOE 2/2 mice are elevated in plasma following lipopolysaccharide injection or when fed a highfat diet, comparable to observations with the E4 allele. 40, 41 If APOE has similar immunomodulatory functions in the CNS, loss of the more "favorable" APOE genotypes may contribute to neuroinflammation seen in HIV infection. Microglia may also contribute to HIV-associated cognitive impairment through loss of neurotrophic factors that help spare neurons from injury or death. Our studies reveal several key neurotrophic factors are downregulated in both HIV groupings but most only reach statistical significance in HIVE. Reduced or lost microglial production of neurotrophic factors suggests an additional mechanism of neuropathogenesis and underscores the role microglia potentially play in brain homeostasis by supporting neuronal function and survival through paracrine mechanisms, as well as regulating microglial activation through autocrine mechanisms.
In the GO categories of transcription factors, kinases, and phosphatases, downregulation was primarily observed, apart from Akap1 and Mapk1. The encoded product of Akap1 binds the 2 regulatory subunits of the cyclic adenosine monophosphate (cAMP)-dependent protein kinase A (PKA) and anchors the enzyme to the mitochondrial membrane. This compartmentalizes cAMP-PKA signaling to the mitochondria through PKA activation of the cAMP response element-binding protein (CREB), which is bound to mitochondrial DNA. 42, 43 Increased Akap1 transcription in HIV may be in response to CREB, which is also reduced at the RNA level in both HIV groupings. This may suggest impaired mitochondrial function and metabolic stress caused by chronic immune activation. Neuroinflammation may also influence upregulation of Mapk1, which has been shown to repress transcription of many genes in the context of chronic inflammation, including those induced by interferon c. 44 Although our findings are intriguing and provide important insights into microglial function/loss of function in healthy and diseased brain, there are study limitations. LCM was performed on formalin-fixed, paraffinembedded brain tissue acquired from autopsy, which can impair the quality of extracted RNA. To lessen this concern, tissues were acquired from an NNTC site and collected within the same protocol and defined postmortem interval. IHC was performed using a high-heat antigen retrieval method that interferes with formalin crosslinking of RNA, DNA, and protein and we collected many cells from each case. Extracted RNA was amplified using a TC RNA amplification to limit amplification bias and increase the reliability of comparisons between groups. Additionally, we were unable to validate our findings by quantitative polymerase chain reaction (qPCR), due to low RNA yields and lack of matched frozen tissues. We previously tried to validate single population microarray findings via qPCR from single-and double-labeled LCM-captured neurons from paraffinembedded postmortem human tissue sections with equivocal results, [45] [46] [47] suggesting RNA abundance is the limiting factor in fixed tissues and is not specific to HIVinfected cohorts. Even with qPCR validation, the question remains of whether abnormal levels of transcripts result in similar changes to protein expression and/or function. For example, in our subjects, Casp1 showed significant downregulation in HIVE; yet, prior immunohistochemical analyses of HIVE patients demonstrated significant increases in microglial caspase 1 staining compared to controls. 48 In our current study, we found significantly decreased NFjB transcripts in HIVE brain, as compared to HIV/noE, yet transcription of IL-1b and IL6, which is regulated by NFjB, is elevated. This may be a reflection of the complexities of NFjB signaling, where activated cytoplasmic NFjB may continue to participate in transcriptional activity even while NFjB production is reduced. TNFa signaling through TNFRSF1A, which is also upregulated in HIVE, induces NFjB activation. Although we do not know whether TNFa production is increased in our patients, previous immunohistochemical studies have shown microglia-associated TNFa in brain of patients with HIVE 49 and may suggest a mechanism through which proinflammatory cytokine production continues, even in the context of reduced NFjB transcription. Despite these limitations, our work has yielded unparalleled insight and new avenues of investigation into the role of microglia in health and disease, particularly within the context of chronic HIV infection. Additional studies are needed to better understand the mechanisms driving the observed differential gene regulation and their consequences, which cannot infer causality in postmortem tissue.
In summary, single-population custom-designed microarray analysis demonstrates numerous microglial genes are significantly altered in HIV infection, even in the absence of encephalitis or detectable virus in brain. Changes in microglial transcripts related to immune activation and function, kinases, phosphatases, and pro-/antiapoptotic and neurotrophic factors suggest several possible mechanisms of neuronal injury or death. Most of the significantly altered transcripts in HIVE displayed intermediate changes in HIV/noE but with impaired cognition, supporting the notion that the varying degrees of HAND are a continuum of the same pathogenic processes. Additionally, our microarray results indicate the utility of profiling brain MUs/microglia in HIV infection to ascertain alterations in specific pathways, genes, and presumably encoded proteins that may be amenable to targeted treatment modalities.
